<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37894054</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-2607</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>26</Day></PubDate></JournalIssue><Title>Microorganisms</Title><ISOAbbreviation>Microorganisms</ISOAbbreviation></Journal><ArticleTitle>High Levels of IL-1&#x3b2;, TNF-&#x3b1; and MIP-1&#x3b1; One Month after the Onset of the Acute SARS-CoV-2 Infection, Predictors of Post COVID-19 in Hospitalized Patients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2396</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/microorganisms11102396</ELocationID><Abstract><AbstractText>The pandemic caused by SARS-CoV-2 infection has left behind a new symptomatology called post COVID-19, or "long COVID". The pathophysiological mechanisms still remain controversial; however, a link between persistent inflammation and these sequelae has been suggested. Herein, we longitudinally assessed up- and downstream molecules of the NLRP3 inflammasome's pathway in three study groups: healthy donors (HC, n = 14) and donors with a confirmed SARS-CoV-2 infection who had been hospitalized, the latter divided into post COVID-19 (PC, n = 27) and non-post COVID-19 patients (nPC, n = 27) based on the presence or absence of symptomatology at month 6, respectively. Plasma cytokines (IL-1&#x3b2;, IL-3, IL-6, IL-8, IL-18, IP-10, MIG, TNF-&#x3b1;, IFN-&#x3b3;, MIP-1&#x3b1; and MIP-1&#x3b2;) and total peroxide (TPX) levels were quantified at baseline and at months 1 and 6 after the onset of the infection. Baseline values were the highest for both TPX and cytokines that progressively decreased thereafter the acute infection. IL-1&#x3b2;, MIP-1&#x3b1; and TNF-&#x3b1; at month 1 were the only cytokines that showed a significant difference between nPC and PC. These findings suggest that a persistent inflammatory state one month after the onset of SARS-CoV-2 infection related to specific cytokines (IL-1&#x3b2;, MIP-1&#x3b1;, and TNF-&#x3b1;) might guide to predicting post COVID-19 symptomatology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alonso-Dom&#xed;nguez</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Virology and Pathogenesis, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallego-Rodr&#xed;guez</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Virology and Pathogenesis, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez-Barros</LastName><ForeName>In&#xe9;s</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Virology and Pathogenesis, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calder&#xf3;n-Cruz</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-2501-9667</Identifier><AffiliationInfo><Affiliation>Statistics and Methodology Unit, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leiro-Fern&#xe1;ndez</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Pneumology Department, Complexo Hospitalario Universitario de Vigo (CHUVI), Sergas, 36312 Vigo, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeumoVigo I+i Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Gonz&#xe1;lez</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4836-6768</Identifier><AffiliationInfo><Affiliation>Virology and Pathogenesis, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poveda</LastName><ForeName>Eva</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-4835-9875</Identifier><AffiliationInfo><Affiliation>Virology and Pathogenesis, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P19/00747</GrantID><Agency>Instituto de Investigaci&#xf3;n Carlos III</Agency><Country/></Grant><Grant><GrantID>PI22/01341</GrantID><Agency>Instituto de Investigaci&#xf3;n Carlos III</Agency><Country/></Grant><Grant><GrantID>CM20/00243</GrantID><Agency>Instituto de Investigaci&#xf3;n Carlos III</Agency><Country/></Grant><Grant><GrantID>IN606A-2022</GrantID><Agency>Axencia Galega de Innovaci&#xf3;n</Agency><Country/></Grant><Grant><GrantID>CI22-A-02</GrantID><Agency>Galicia Sur Biomedical Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Microorganisms</MedlineTA><NlmUniqueID>101625893</NlmUniqueID><ISSNLinking>2076-2607</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cytokines</Keyword><Keyword MajorTopicYN="N">post COVID-19</Keyword><Keyword MajorTopicYN="N">symptomatology</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>28</Day><Hour>11</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>28</Day><Hour>11</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>28</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37894054</ArticleId><ArticleId IdType="pmc">PMC10609568</ArticleId><ArticleId IdType="doi">10.3390/microorganisms11102396</ArticleId><ArticleId IdType="pii">microorganisms11102396</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sharma A., Tiwari S., Deb M.K., Marty J.L. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): A Global Pandemic and Treatment Strategies. Int. J. Antimicrob. Agents. 2020;56:106054. doi: 10.1016/j.ijantimicag.2020.106054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106054</ArticleId><ArticleId IdType="pmc">PMC7286265</ArticleId><ArticleId IdType="pubmed">32534188</ArticleId></ArticleIdList></Reference><Reference><Citation>With the International Public Health Emergency Ending, WHO/Europe Launches Its Transition Plan for COVID-19.  [(accessed on 25 August 2023)].  Available online:  https://www.who.int/europe/news/item/12-06-2023-with-the-international-public-health-emergency-ending--who-europe-launches-its-transition-plan-for-covid-19.</Citation></Reference><Reference><Citation>Lai C.-C., Shih T.-P., Ko W.-C., Tang H.-J., Hsueh P.-R. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease-2019 (COVID-19): The Epidemic and the Challenges. Int. J. Antimicrob. Agents. 2020;55:105924. doi: 10.1016/j.ijantimicag.2020.105924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105924</ArticleId><ArticleId IdType="pmc">PMC7127800</ArticleId><ArticleId IdType="pubmed">32081636</ArticleId></ArticleIdList></Reference><Reference><Citation>Montani D., Savale L., Noel N., Meyrignac O., Colle R., Gasnier M., Corruble E., Beurnier A., Jutant E.-M., Pham T., et al. Post-Acute COVID-19 Syndrome. Eur. Respir. Rev. 2022;31:210185. doi: 10.1183/16000617.0185-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/16000617.0185-2021</ArticleId><ArticleId IdType="pmc">PMC8924706</ArticleId><ArticleId IdType="pubmed">35264409</ArticleId></ArticleIdList></Reference><Reference><Citation>Post COVID-19 Condition (Long COVID)  [(accessed on 4 July 2023)].  Available online:  https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition#:~:text=Definition,months%20with%20no%20other%20explanation.</Citation></Reference><Reference><Citation>Romero-Duarte &#xc1;., Rivera-Izquierdo M., Guerrero-Fern&#xe1;ndez de Alba I., P&#xe9;rez-Contreras M., Fern&#xe1;ndez-Mart&#xed;nez N.F., Ruiz-Montero R., Serrano-Ortiz &#xc1;., Gonz&#xe1;lez-Serna R.O., Salcedo-Leal I., Jim&#xe9;nez-Mej&#xed;as E., et al. Sequelae, Persistent Symptomatology and Outcomes after COVID-19 Hospitalization: The ANCOHVID Multicentre 6-Month Follow-up Study. BMC Med. 2021;19:129. doi: 10.1186/s12916-021-02003-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02003-7</ArticleId><ArticleId IdType="pmc">PMC8134820</ArticleId><ArticleId IdType="pubmed">34011359</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlgren C., Forsberg G., Divanoglou A., &#xd6;stholm Balkhed &#xc5;., Niward K., Berg S., Levi R. Two-Year Follow-up of Patients with Post-COVID-19 Condition in Sweden: A Prospective Cohort Study. Lancet Reg. Health-Eur. 2023;28:100595. doi: 10.1016/j.lanepe.2023.100595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2023.100595</ArticleId><ArticleId IdType="pmc">PMC9951394</ArticleId><ArticleId IdType="pubmed">36855599</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major Findings, Mechanisms and Recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Maamar M., Artime A., Pariente E., Fierro P., Ruiz Y., Guti&#xe9;rrez S., Tobalina M., D&#xed;az-Salazar S., Ramos C., Olmos J.M., et al. Post-COVID-19 Syndrome, Low-Grade Inflammation and Inflammatory Markers: A Cross-Sectional Study. Curr. Med. Res. Opin. 2022;38:901&#x2013;909. doi: 10.1080/03007995.2022.2042991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2022.2042991</ArticleId><ArticleId IdType="pmc">PMC8935459</ArticleId><ArticleId IdType="pubmed">35166141</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Huang S., Yin L. The Cytokine Storm and COVID-19. J. Med. Virol. 2021;93:250&#x2013;256. doi: 10.1002/jmv.26232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26232</ArticleId><ArticleId IdType="pmc">PMC7361342</ArticleId><ArticleId IdType="pubmed">32592501</ArticleId></ArticleIdList></Reference><Reference><Citation>Diarimalala R.O., Wei Y., Hu D., Hu K. Inflammasomes during SARS-CoV-2 Infection and Development of Their Corresponding Inhibitors. Front. Cell Infect. Microbiol. 2023;13:1218039. doi: 10.3389/fcimb.2023.1218039.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2023.1218039</ArticleId><ArticleId IdType="pmc">PMC10288989</ArticleId><ArticleId IdType="pubmed">37360532</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams E.S., Martins T.B., Shah K.S., Hill H.R., Coiras M., Spivak A.M., Planelles V. Cytokine Deficiencies in Patients with Long-COVID. J. Clin. Cell Immunol. 2022;13:672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9894377</ArticleId><ArticleId IdType="pubmed">36742994</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Lu S., Tang A.F., Durstenfeld M.S., Ho H., Goldberg S.A., Forman C.A., Munter S.E., Hoh R., Tai V., et al. Markers of Immune Activation and Inflammation in Individuals with Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J. Infect. Dis. 2021;224:1839&#x2013;1848. doi: 10.1093/infdis/jiab490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Ampudia Y., Monsalve D.M., Rojas M., Rodr&#xed;guez Y., Zapata E., Ram&#xed;rez-Santana C., Anaya J.-M. Persistent Autoimmune Activation and Proinflammatory State in Post-Coronavirus Disease 2019 Syndrome. J. Infect. Dis. 2022;225:2155&#x2013;2162. doi: 10.1093/infdis/jiac017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac017</ArticleId><ArticleId IdType="pmc">PMC8903340</ArticleId><ArticleId IdType="pubmed">35079804</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai Y.-J., Liu S.-H., Manachevakul S., Lee T.-A., Kuo C.-T., Bello D. Biomarkers in Long COVID-19: A Systematic Review. Front. Med. 2023;10:1085988. doi: 10.3389/fmed.2023.1085988.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1085988</ArticleId><ArticleId IdType="pmc">PMC9895110</ArticleId><ArticleId IdType="pubmed">36744129</ArticleId></ArticleIdList></Reference><Reference><Citation>Montazersaheb S., Hosseiniyan Khatibi S.M., Hejazi M.S., Tarhriz V., Farjami A., Ghasemian Sorbeni F., Farahzadi R., Ghasemnejad T. COVID-19 Infection: An Overview on Cytokine Storm and Related Interventions. Virol. J. 2022;19:92. doi: 10.1186/s12985-022-01814-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01814-1</ArticleId><ArticleId IdType="pmc">PMC9134144</ArticleId><ArticleId IdType="pubmed">35619180</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Zhang C., Huang F., Yang Y., Wang F., Yuan J., Zhang Z., Qin Y., Li X., Zhao D., et al. Elevated Plasma Levels of Selective Cytokines in COVID-19 Patients Reflect Viral Load and Lung Injury. Natl. Sci. Rev. 2020;7:1003&#x2013;1011. doi: 10.1093/nsr/nwaa037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nsr/nwaa037</ArticleId><ArticleId IdType="pmc">PMC7107806</ArticleId><ArticleId IdType="pubmed">34676126</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle D.M., Kim-Schulze S., Huang H.-H., Beckmann N.D., Nirenberg S., Wang B., Lavin Y., Swartz T.H., Madduri D., Stock A., et al. An Inflammatory Cytokine Signature Predicts COVID-19 Severity and Survival. Nat. Med. 2020;26:1636&#x2013;1643. doi: 10.1038/s41591-020-1051-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1051-9</ArticleId><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Codina H., Vieitez I., Gutierrez-Valencia A., Skouridou V., Mart&#xed;nez C., Pati&#xf1;o L., Botero-Gallego M., Trujillo-Rodr&#xed;guez M., Serna-Gallego A., Mu&#xf1;oz-Muela E., et al. Elevated Anti-SARS-CoV-2 Antibodies and IL-6, IL-8, MIP-1&#x3b2;, Early Predictors of Severe COVID-19. Microorganisms. 2021;9:2259. doi: 10.3390/microorganisms9112259.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9112259</ArticleId><ArticleId IdType="pmc">PMC8624589</ArticleId><ArticleId IdType="pubmed">34835384</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahallawi W.H., Khabour O.F., Zhang Q., Makhdoum H.M., Suliman B.A. MERS-CoV Infection in Humans Is Associated with a pro-Inflammatory Th1 and Th17 Cytokine Profile. Cytokine. 2018;104:8&#x2013;13. doi: 10.1016/j.cyto.2018.01.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2018.01.025</ArticleId><ArticleId IdType="pmc">PMC7129230</ArticleId><ArticleId IdType="pubmed">29414327</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C.K., Lam C.W.K., Wu A.K.L., Ip W.K., Lee N.L.S., Chan I.H.S., Lit L.C.W., Hui D.S.C., Chan M.H.M., Chung S.S.C., et al. Plasma Inflammatory Cytokines and Chemokines in Severe Acute Respiratory Syndrome. Clin. Exp. Immunol. 2004;136:95&#x2013;103. doi: 10.1111/j.1365-2249.2004.02415.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2004.02415.x</ArticleId><ArticleId IdType="pmc">PMC1808997</ArticleId><ArticleId IdType="pubmed">15030519</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury S.M., Ma X., Abdullah S.W., Zheng H. Activation and Inhibition of the NLRP3 Inflammasome by RNA Viruses. J. Inflamm. Res. 2021;14:1145&#x2013;1163. doi: 10.2147/JIR.S295706.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S295706</ArticleId><ArticleId IdType="pmc">PMC8009543</ArticleId><ArticleId IdType="pubmed">33814921</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C., Willscher E., Paschold L., Gottschick C., Klee B., Henkes S.-S., Bosurgi L., Dutzmann J., Sedding D., Frese T., et al. The IL-1&#x3b2;, IL-6, and TNF Cytokine Triad Is Associated with Post-Acute Sequelae of COVID-19. Cell Rep. Med. 2022;3:100663. doi: 10.1016/j.xcrm.2022.100663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100663</ArticleId><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriazopoulou E., Huet T., Cavalli G., Gori A., Kyprianou M., Pickkers P., Eugen-Olsen J., Clerici M., Veas F., Chatellier G., et al. Effect of Anakinra on Mortality in Patients with COVID-19: A Systematic Review and Patient-Level Meta-Analysis. Lancet Rheumatol. 2021;3:e690&#x2013;e697. doi: 10.1016/S2665-9913(21)00216-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00216-2</ArticleId><ArticleId IdType="pmc">PMC8352496</ArticleId><ArticleId IdType="pubmed">34396156</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson B.K., Francisco E.B., Yogendra R., Long E., Pise A., Rodrigues H., Hall E., Herrera M., Parikh P., Guevara-Coto J., et al. Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection. Front. Immunol. 2022;12:746021. doi: 10.3389/fimmu.2021.746021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.746021</ArticleId><ArticleId IdType="pmc">PMC8784688</ArticleId><ArticleId IdType="pubmed">35082777</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoni A., Penco F., Mollica H., Bocca P., Prigione I., Corcione A., Cangelosi D., Schena F., Del Zotto G., Amaro A., et al. Spontaneous NLRP3 Inflammasome-Driven IL-1-&#x3b2; Secretion Is Induced in Severe COVID-19 Patients and Responds to Anakinra Treatment. J. Allergy Clin. Immunol. 2022;150:796&#x2013;805. doi: 10.1016/j.jaci.2022.05.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2022.05.029</ArticleId><ArticleId IdType="pmc">PMC9272569</ArticleId><ArticleId IdType="pubmed">35835255</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan P., Shen M., Yu Z., Ge W., Chen K., Tian M., Xiao F., Wang Z., Wang J., Jia Y., et al. SARS-CoV-2 N Protein Promotes NLRP3 Inflammasome Activation to Induce Hyperinflammation. Nat. Commun. 2021;12:4664. doi: 10.1038/s41467-021-25015-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25015-6</ArticleId><ArticleId IdType="pmc">PMC8329225</ArticleId><ArticleId IdType="pubmed">34341353</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiroz M.A.F., das Neves P.F.M., Lima S.S., da Lopes J.C., da Torres M.K.S., Vallinoto I.M.V.C., Bichara C.D.A., dos Santos E.F., de Brito M.T.F.M., da Silva A.L.S., et al. Cytokine Profiles Associated With Acute COVID-19 and Long COVID-19 Syndrome. Front. Cell Infect. Microbiol. 2022;12:922422. doi: 10.3389/fcimb.2022.922422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.922422</ArticleId><ArticleId IdType="pmc">PMC9279918</ArticleId><ArticleId IdType="pubmed">35846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Ruiz J., Lomel&#xed;n-Gasc&#xf3;n J., Lira Luna J., Vargas-Castro A.S., P&#xe9;rez-Fragoso A., Nu&#xf1;ez-Aguirre M., Alcal&#xe1;-Carmona B., Absal&#xf3;n-Aguilar A., Balderas-Miranda J.T., Maravillas-Montero J.L., et al. Novel Clinical and Immunological Features Associated with Persistent Post-Acute Sequelae of COVID-19 after Six Months of Follow-up: A Pilot Study. Infect. Dis. 2023;55:243&#x2013;254. doi: 10.1080/23744235.2022.2158217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2022.2158217</ArticleId><ArticleId IdType="pubmed">36637466</ArticleId></ArticleIdList></Reference><Reference><Citation>Newell K.L., Waickman A.T. Inflammation, Immunity, and Antigen Persistence in Post-Acute Sequelae of SARS-CoV-2 Infection. Curr. Opin. Immunol. 2022;77:102228. doi: 10.1016/j.coi.2022.102228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2022.102228</ArticleId><ArticleId IdType="pmc">PMC9127180</ArticleId><ArticleId IdType="pubmed">35724449</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Mak J.W.Y., Su Q., Yeoh Y.K., Lui G.C.-Y., Ng S.S.S., Zhang F., Li A.Y.L., Lu W., Hui D.S.-C., et al. Gut Microbiota Dynamics in a Prospective Cohort of Patients with Post-Acute COVID-19 Syndrome. Gut. 2022;71:544&#x2013;552. doi: 10.1136/gutjnl-2021-325989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325989</ArticleId><ArticleId IdType="pubmed">35082169</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Gonz&#xe1;lez A., Ara&#xfa;jo-Ameijeiras A., Fern&#xe1;ndez-Villar A., Crespo M., Poveda E., Cabrera J.J., del Campo V., de Araujo B.G., G&#xf3;mez C., Leiro V., et al. Long COVID in Hospitalized and Non-Hospitalized Patients in a Large Cohort in Northwest Spain, a Prospective Cohort Study. Sci. Rep. 2022;12:3369. doi: 10.1038/s41598-022-07414-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-07414-x</ArticleId><ArticleId IdType="pmc">PMC8888560</ArticleId><ArticleId IdType="pubmed">35233035</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>